Ultrasound performance using the EU-TIRADS score in the diagnosis of thyroid cancer in Congolese hospitals.

John Bukasa-Kakamba, Pascal Bayauli, Nadia Sabbah, Joseph Bidingija, Ali Atoot, Branly Mbunga, Aliocha Nkodila, Adam Atoot, Ayrton Ilolo Bangolo, Jean Rene M'Buyamba-Kabangu
Author Information
  1. John Bukasa-Kakamba: Department of Endocrinology, Metabolism and Nuclear Medicine, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo. johnbukasa73@gmail.com.
  2. Pascal Bayauli: Department of Endocrinology, Metabolism and Nuclear Medicine, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo.
  3. Nadia Sabbah: Department of Endocrinology, Metabolism and Nutrition, André Rosemon Hospital Center, University of Cayenne, Cayenne, French Guiana.
  4. Joseph Bidingija: Department of Endocrinology, Metabolism and Nuclear Medicine, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo.
  5. Ali Atoot: Department of Anesthesia, Hackensack University Medical Center, Hackensack, NJ, USA.
  6. Branly Mbunga: Department of Family Medicine, Protestant University of Congo, Kinshasa, Democratic Republic of the Congo.
  7. Aliocha Nkodila: School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  8. Adam Atoot: Department of Internal Medicine, Hackensack University Medical Center/Palisades Medical Center, North Bergen, NJ, USA.
  9. Ayrton Ilolo Bangolo: Department of Internal Medicine, Hackensack University Medical Center/Palisades Medical Center, North Bergen, NJ, USA. ayrtonbangolo@yahoo.com.
  10. Jean Rene M'Buyamba-Kabangu: Department of Endocrinology, Metabolism and Nuclear Medicine, Kinshasa University Clinics, Kinshasa, Democratic Republic of the Congo. jerembu@yahoo.fr.

Abstract

The thyroid imaging reporting and data systems by the European thyroid Association (EU-TIRADS) has been widely used in malignancy risk stratification of thyroid nodules. However, there is a paucity of data in developing countries, especially in Africa, to validate the use of this scoring system. The aim of the study was to assess the diagnostic value of the EU-TIRADS score in Congolese hospitals, using pathological examination after surgery as the gold standard in Congolese hospitals. This retrospective and analytical study examined clinical, ultrasound and pathological data of 549 patients aged 45 ± 14 years, including 468 females (85.2%), operated for thyroid nodule between January 2005 and January 2019. In the present study, only the highest graded nodule according to the EU-TIRADS score in each patient was taken into account for the statistical analyses. So 549 nodules were considered. Nodules classified EU-TIRADS 2 and 3 on the one hand, and, on the other hand, 4 and 5, were considered respectively at low and high risk of malignancy. The sensitivity and specificity of the EU-TIRADS score were calculated. The significance level was set at 5%. Of all patients, 21.7% had malignant nodules. They made 48.4% of the nodules in patients younger than and at 20 years old, and 31.1% in those aged 60 or over. Malignant nodules were more frequent in men than in women (30.9% vs. 20.1%; p = 0.024). Papillary carcinoma (67.2%) and follicular carcinoma (21.8%) were the main types. The malignancy rate was 39.7% and 1.5% among nodules rated EU-TIRADS 4 and 5, and those with EU-TIRADS score 2 and 3, respectively (p < 0.001). The EU-TIRADS score had a sensitivity of 96.6% and a specificity of 59.3%. The ROC curve indicated an area under the curve of 0.862. In a low-income country, a well performed thyroid ultrasound, using the EU-TIRADS score, could be an important tool in the selection of thyroid nodules suspected of malignancy and requiring histopathological examination in the Congolese hospital setting.Trial registration: The research protocol had obtained the favorable opinion of the DRC national health ethics committee no. 197/CNES/BN/PMMF/2020. The data was collected and analyzed anonymously.

References

  1. Thyroid. 2016 Apr;26(4):562-72 [PMID: 26756476]
  2. Thyroid. 2005 Jul;15(7):708-17 [PMID: 16053388]
  3. Eur J Cancer Prev. 2007 Feb;16(1):62-70 [PMID: 17220706]
  4. Thyroid. 2006 Feb;16(2):109-42 [PMID: 16420177]
  5. Front Oncol. 2021 Apr 27;11:575166 [PMID: 33987082]
  6. Future Oncol. 2010 Nov;6(11):1771-9 [PMID: 21142662]
  7. Eur Thyroid J. 2017 Sep;6(5):225-237 [PMID: 29167761]
  8. J Radiol. 2011 Jul-Aug;92(7-8):701-13 [PMID: 21819912]
  9. BMC Cancer. 2014 Dec 18;14:975 [PMID: 25519305]
  10. AJR Am J Roentgenol. 2010 Jan;194(1):44-54 [PMID: 20028904]
  11. Thyroid. 2007 May;17(5):461-6 [PMID: 17542676]
  12. Presse Med. 2011 Sep;40(9 Pt 1):793-826 [PMID: 22232784]
  13. Eur J Endocrinol. 2013 Apr 15;168(5):649-55 [PMID: 23416955]
  14. Cancer Causes Control. 2009 Jul;20(5):525-31 [PMID: 19016336]
  15. Pan Afr Med J. 2018 Sep 20;31:43 [PMID: 30918569]
  16. Thyroid. 2010 Oct;20(10):1145-50 [PMID: 20860422]
  17. J Otolaryngol Head Neck Surg. 2013 Dec 20;42:61 [PMID: 24359603]
  18. Thyroid. 2007 Dec;17(12):1269-76 [PMID: 17988196]
  19. Pan Afr Med J. 2015 May 26;21:59 [PMID: 26405495]
  20. Pan Afr Med J. 2016 Mar 15;23:88 [PMID: 27222685]
  21. Ger Med Sci. 2010 Feb 02;8:Doc02 [PMID: 20200655]
  22. Thyroid. 2017 Dec;27(12):1490-1497 [PMID: 29020892]
  23. Endocr Pract. 2006 Jan-Feb;12(1):63-102 [PMID: 16596732]
  24. Radiology. 2016 Mar;278(3):917-24 [PMID: 26348102]
  25. Ann Endocrinol (Paris). 2011 Apr;72(2):136-48 [PMID: 21513910]
  26. Cancer Cytopathol. 2020 Jul;128(7):470-481 [PMID: 32078249]
  27. Eur J Endocrinol. 2020 Nov;183(5):521-528 [PMID: 32841935]
  28. Ann Endocrinol (Paris). 2010 Mar;71(2):95-101 [PMID: 20036351]
  29. Ultrasonography. 2016 Jan;35(1):25-38 [PMID: 26324117]
  30. Diagn Cytopathol. 2012 May;40(5):399-403 [PMID: 21681976]
  31. Thyroid. 2016 Jan;26(1):1-133 [PMID: 26462967]
  32. Thyroid. 2009 Nov;19(11):1215-23 [PMID: 19888859]
  33. J Radiol. 2009 Mar;90(3 Pt 2):362-70 [PMID: 19421127]
  34. Cytojournal. 2008 Apr 07;5:6 [PMID: 18394201]

MeSH Term

Male
Humans
Female
Young Adult
Adult
Thyroid Nodule
Retrospective Studies
Risk Assessment
Thyroid Neoplasms
Ultrasonography
Hospitals

Word Cloud

Created with Highcharts 10.0.0EU-TIRADSnodulesscorethyroiddatamalignancyCongolesestudyhospitalsusingpatientsriskpathologicalexaminationultrasound549aged2%noduleJanuaryconsidered23hand45respectivelysensitivityspecificity5%217%1%carcinomacurveimagingreportingsystemsEuropeanThyroidAssociation haswidelyusedstratificationHoweverpaucitydevelopingcountriesespeciallyAfricavalidateusescoringsystemaimassessdiagnosticvaluesurgerygoldstandardretrospectiveanalyticalexaminedclinical45 ± 14 yearsincluding468females85operated20052019presenthighestgradedaccordingpatienttakenaccountstatisticalanalysesNodulesclassifiedonelowhighcalculatedsignificancelevelsetmalignantmade484%younger20 yearsold3160Malignantfrequentmenwomen309%vs20p = 0024Papillary67follicular8%maintypesrate391amongratedp < 0001966%593%ROCindicatedarea0862low-incomecountrywellperformedimportanttoolselectionsuspectedrequiringhistopathologicalhospitalsettingTrialregistration:researchprotocolobtainedfavorableopinionDRCnationalhealthethicscommittee197/CNES/BN/PMMF/2020collectedanalyzedanonymouslyUltrasoundperformancediagnosiscancer

Similar Articles

Cited By